TG Therapeutics (NASDAQ: TGTX) reported Q1 EPS of $0.12, $0.16 worse than the analyst estimate of $0.28. Revenue for the quarter came in at $194.8 million versus the consensus estimate of $199.45 million.

GUIDANCE:

TG Therapeutics sees FY2026 revenue of $925 million, versus the consensus of $900.3 million.
Raises full year 2026 target BRIUMVI U.S. net product revenue to approximately $885 - $900 million (prior guidance of $825-$850 million)
Provides second quarter 2026 target BRIUMVI U.S. net product revenue of approximately $220 million
Full year 2026 target operating expense, defined as R&D and SG&A, of approximately $350 million excluding non-cash compensation, in addition to approximately $100 million in expenses associated with the subcutaneous BRIUMVI manufacturing costs and secondary manufacturer start-up costs

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.